Evidence map›Paper›PMID 37716594›Full record

ArticleMolecular metabolism2023

Hepatic pyruvate and alanine metabolism are critical and complementary for maintenance of antioxidant capacity and resistance to oxidative insult.

Nicole K H Yiew, Joel H Vazquez, Michael R Martino, Stefanie Kennon-McGill, Jake R Price, Felicia D Allard, Eric U Yee, Alexander J Layman, Laura P James, Kyle S McCommis and 2 more

Open access · goldAbstract read
In one paragraph

Article in Molecular metabolism, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
6.2field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 25 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Animals : an open access journal from MDPI · 2025
    Review
  7. Article
  8. NAPQI is absent in the mouse brain after sub-hepatotoxic and hepatotoxic doses of acetaminophen.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. The Role of Mechanistic Biomarkers in Understanding Acetaminophen Hepatotoxicity in Humans.Drug metabolism and disposition: the biological fate of chemicals · 2024
    Review
  16. Article
  17. Glutaminolysis is a Potential Therapeutic Target for Kidney Diseases.Diabetes, metabolic syndrome and obesity : targets and therapy · 2024
    Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Nicole K H YiewDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Joel H VazquezDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Department of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Michael R MartinoDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Stefanie Kennon-McGillDepartment of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Jake R PriceDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Department of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Felicia D AllardDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Eric U YeeDepartment of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Alexander J LaymanDepartment of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Laura P JamesDepartment of Pediatrics, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.
Kyle S McCommisDepartment of Biochemistry and Molecular Biology, Saint Louis University School of Medicine, St. Louis, MO, USA.
Brian N FinckDepartment of Medicine, Washington University School of Medicine, St. Louis, MO, USA.
Mitchell R McGillDepartment of Pharmacology and Toxicology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, 72205, USA; Department of Environmental Health Sciences, Fay W. Boozman College of Public Health, University of Arkansas for Medical Sciences, Little Rock, AR, USA; Department of Pathology, College of Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA. Electronic address: mmcgill@uams.edu.
University of Arkansas for Medical Sciences · USWashington University in St. Louis · USSaint Louis University · US

Funding

Washington University Nutrition Obesity Research CenterP30DK056341 · NIDDK · WASHINGTON UNIVERSITY · PI Dominic N Reeds · 1999 to 2026
$30.2M
Expanding Translational Research in ArkansasUL1TR003107 · NCATS · UNIV OF ARKANSAS FOR MED SCIS · PI JAMES, LAURA P · 2019 to 2023
$21.6M
TARGETING THE MITOCHONDRIAL PYRUVATE CARRIER TO TREAT NONALCOHOLIC STEATOHEPATITISR01DK104735 · NIDDK · WASHINGTON UNIVERSITY · PI FINCK, BRIAN N · 2015 to 2025
$7.1M
AcetaSTAT Validation and CommercializationSB1DK079387 · NIDDK · ACETAMINOPHEN TOXICITY DIAGNOSTICS, LLC · PI JAMES, LAURA P · 2022 to 2025
$3.5M
NOVEL ASPECTS OF HEPATIC MITOCHONDRIAL AMINO ACID METABOLISMR01DK117657 · NIDDK · WASHINGTON UNIVERSITY · PI FINCK, BRIAN N · 2018 to 2022
$1.9M
Systems Pharmacology and Toxicology Training ProgramT32GM106999 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI PRATHER, PAUL L · 2013 to 2022
$1.4M
NCATS NIH HHS UL1 TR003107NIDDK NIH HHS P30 DK056341NIDDK NIH HHS R01 DK104735NIDDK NIH HHS R01 DK117657NIDDK NIH HHS SB1 DK079387NIGMS NIH HHS T32 GM106999
6 · The paper itself

Abstract

objectiveMitochondrial pyruvate is a critical intermediary metabolite in gluconeogenesis, lipogenesis, and NADH production. As a result, the mitochondrial pyruvate carrier (MPC) complex has emerged as a promising therapeutic target in metabolic diseases. Clinical trials are currently underway. However, recent in vitro data indicate that MPC inhibition diverts glutamine/glutamate away from glutathione synthesis and toward glutaminolysis to compensate for loss of pyruvate oxidation, possibly sensitizing cells to oxidative insult. Here, we explored this in vivo using the clinically relevant acetaminophen (APAP) overdose model of acute liver injury, which is driven by oxidative stress.

methodsWe used pharmacological and genetic approaches to inhibit MPC2 and alanine aminotransferase 2 (ALT2), individually and concomitantly, in mice and cell culture models and determined the effects on APAP hepatotoxicity.

resultsWe found that MPC inhibition sensitizes the liver to APAP-induced injury in vivo only with concomitant loss of alanine aminotransferase 2 (ALT2). Pharmacological and genetic manipulation of neither MPC2 nor ALT2 alone affected APAP toxicity, but liver-specific double knockout (DKO) significantly worsened APAP-induced liver damage. Further investigation indicated that DKO impaired glutathione synthesis and increased urea cycle flux, consistent with increased glutaminolysis, and these results were reproducible in vitro. Finally, induction of ALT2 and post-treatment with dichloroacetate both reduced APAP-induced liver injury, suggesting new therapeutic avenues.

conclusionsIncreased susceptibility to APAP toxicity requires loss of both the MPC and ALT2 in vivo, indicating that MPC inhibition alone is insufficient to disrupt redox balance. Furthermore, the results from ALT2 induction and dichloroacetate in the APAP model suggest new metabolic approaches to the treatment of liver damage.

Indexed as

Chemical and Drug Induced Liver InjuryLiver DiseasesAcetaminophenAlanineAlanine TransaminaseAnimalsAntioxidantsGlutathioneMiceOxidation-ReductionOxidative StressPyruvic AcidAcetaminophenAlanineAlanine TransaminaseAntioxidantsGlutathionePyruvic AcidAcetaminophenDiabetesGlutathioneLiverMetabolismOxidative stress

Identifiers

PMID37716594
PMCPMC10561123
OpenAlexW4386778804

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.